XNASKYMR
Market cap2.47bUSD
Jan 10, Last price
38.17USD
1D
-5.80%
1Q
-15.22%
IPO
34.21%
Name
Kymera Therapeutics Inc
Chart & Performance
P/E
—
P/S
31.45
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
23.72%
Rev. gr., 5y
%
Revenues
79m
+67.84%
Net income
-147m
L-3.21%
CFO
-103m
L-32.83%
Earnings
Feb 20, 2025
Profile
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 78,592 67.84% | 46,826 -35.71% | ||||
Cost of revenue | 433,203 | 211,059 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (354,611) | (164,233) | ||||
NOPBT Margin | ||||||
Operating Taxes | (2,977) | |||||
Tax Rate | ||||||
NOPAT | (354,611) | (161,256) | ||||
Net income | (146,962) -3.21% | (151,831) 54.94% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 4,268 | 149,825 | ||||
BB yield | -0.29% | -11.13% | ||||
| Debt | ||||||
Debt current | 12,690 | 3,943 | ||||
Long-term debt | 241,332 | 30,727 | ||||
Deferred revenue | 16,768 | 28,000 | ||||
Other long-term liabilities | (78,329) | 8,331 | ||||
Net debt | (182,293) | (677,152) | ||||
| Cash flow | ||||||
Cash from operating activities | (102,826) | (153,085) | ||||
CAPEX | (34,480) | (2,836) | ||||
Cash from investing activities | 139,886 | 20,519 | ||||
Cash from financing activities | 4,192 | 152,999 | ||||
FCF | (442,356) | (162,709) | ||||
| Balance | ||||||
Cash | 374,881 | 559,494 | ||||
Long term investments | 61,434 | 152,328 | ||||
Excess cash | 432,385 | 709,481 | ||||
Stockholders' equity | (531,298) | (388,733) | ||||
Invested Capital | 1,034,056 | 932,550 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 58,365 | 53,933 | ||||
Price | 25.46 2.00% | 24.96 -60.69% | ||||
Market cap | 1,485,986 10.39% | 1,346,173 -55.82% | ||||
EV | 1,303,693 | 669,021 | ||||
EBITDA | (351,046) | (161,256) | ||||
EV/EBITDA | ||||||
Interest | 196 | 176 | ||||
Interest/NOPBT | ||||||